Neogen Corporation (NASDAQ: NEOG) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.03 | Insider Own | 3.29% | Shs Outstand | 218.06M | Perf Week | 10.36% |
| Market Cap | 2.83B | Forward P/E | 31.71 | EPS next Y | 0.41 | Insider Trans | 0.01% | Shs Float | 216.50M | Perf Month | 7.00% |
| Enterprise Value | 3.44B | PEG | - | EPS next Q | 0.05 | Inst Own | - | Short Float | 4.89% | Perf Quarter | 39.63% |
| Income | -7.94M | P/S | 3.26 | EPS this Y | 1133.33% | Inst Trans | - | Short Ratio | 5.36 | Perf Half Y | 49.43% |
| Sales | 870.38M | P/B | 1.35 | EPS next Y | 32.26% | ROA | -0.24% | Short Interest | 10.58M | Perf YTD | 85.98% |
| Book/sh | - | P/C | 34.02 | EPS next 5Y | 14.88% | ROE | -0.37% | 52W High | 13.07 -0.54% | Perf Year | 138.10% |
| Cash/sh | - | P/FCF | 88.86 | EPS past 3/5Y | - | ROIC | -0.60% | 52W Low | 5.10 154.90% | Perf 3Y | -39.32% |
| Dividend Est. | - | EV/EBITDA | 20.01 | Sales past 3/5Y | 1.91% 13.20% | Gross Margin | 46.93% | Volatility | 3.56% 3.33% | Perf 5Y | -69.38% |
| Dividend TTM | - | EV/Sales | 3.96 | EPS Y/Y TTM | 99.40% | Oper. Margin | -2.49% | ATR (14) | 0.43 | Perf 10Y | -41.39% |
| Dividend Ex-Date | - | Quick Ratio | 2.91 | Sales Y/Y TTM | -2.79% | Profit Margin | -0.91% | RSI (14) | 73.85 | Recom | 2.64 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.82 | EPS Q/Q | 280.00% | SMA20 | 8.92% | Beta | 1.78 | Target Price | 13.00 |
| Payout | 0.00% | Debt/Eq | 0.38 | Sales Q/Q | 0.00% | SMA50 | 15.72% | Rel Volume | 3.41 | Prev Close | 12.83 |
| Employees | 2,636 | LT Debt/Eq | 0.38 | Earnings | Oct 06 | SMA200 | 34.70% | Avg Volume | 2.17M | Price | 13.00 |
| IPO Date | Aug 23, 1989 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 58.82% 6.10% | Net Debt/EBITDA | 3.53 | Volume | 7,422,633 | Change | 1.32% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-26-26 | Upgrade | Piper Sandler | Neutral → Overweight | |
| Aug-03-26 | Reiterated | Piper Sandler | Neutral | $10 → $13 |
| Jan-12-26 | Reiterated | Piper Sandler | Neutral | $6.50 → $10 |
| Jan-09-26 | Reiterated | Guggenheim | Buy | $12 |
| Dec-10-25 | Upgrade | CJS Securities | Market Perform → Market Outperform | |
| Oct-16-25 | Reiterated | Piper Sandler | Neutral | $5.00 → $6.50 |
| Jul-29-25 | Downgrade | William Blair | Outperform → Market Perform | |
| Apr-22-25 | Reiterated | Piper Sandler | Neutral | $18 → $5.00 |
| Aug-06-24 | Reiterated | Piper Sandler | Neutral | $17 → $18 |
| Nov-22-22 | Upgrade | William Blair | Market Perform → Outperform |
Neogen Corporation, including its affiliated companies, is a global leader in creating, manufacturing, and distributing a wide range of products crucial for maintaining food quality and animal health. The enterprise is structured into two primary divisions: Food Safety and Animal Safety. The Food Safety segment delivers advanced diagnostic test kits and associated solutions to identify detrimental or unintended contaminants in food and animal feed. This extensive detection capability covers threats such as foodborne pathogens, spoilage-causing organisms, naturally occurring toxins, food allergens, genetically modified ingredients, ruminant by-products, specific meat identification, residual drugs and pesticides, and overall sanitation issues. A key product is the AccuPoint Advanced rapid sanitation test, which quickly spots adenosine triphosphate (ATP), indicating the presence of living cells, to verify cleanliness. Customers for this segment are diverse, encompassing producers and processors of food and feed, grain operations, manufacturers of processed foods like cookies, crackers, candy, and ice cream, as well as those handling meat, poultry, seafood, fruits, vegetables, and dairy. It also serves laboratories and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety division provides a comprehensive portfolio for the animal health market. Offerings include veterinary instruments, pharmaceuticals, vaccines, topical medications, parasiticides, diagnostic products, rodenticides, cleaning agents, disinfectants, insecticides, and genomics testing services. This segment also supplies specialized products for researchers investigating biologically active substances. Its immunoassay test kits are vital for detecting illicit and therapeutic drugs in farm and racing animals, identifying drug residues in meat and meat products, and assisting in human forensic toxicology drug screenings. Moreover, products from this division are instrumental in upholding hygienic conditions and minimizing the risks posed by bacteria, fungi, and viruses. Neogen Corporation was established in 1981 and is headquartered in Lansing, Michigan.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2026 5/31/2026 | FY 2025 5/31/2025 | FY 2024 5/31/2024 | FY 2023 5/31/2023 | FY 2022 5/31/2022 | FY 2021 5/31/2021 | FY 2020 5/31/2020 | FY 2019 5/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 870 | 870 | 895 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 462 | 462 | 473 | — | — | — | — | — | — | |
| Gross Profit | 409 | 409 | 421 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 412 | 412 | 402 | — | — | — | — | — | — | |
| Research and Development | 19 | 18 | 21 | — | — | — | — | — | — | |
| Other Operating Expense | -1 | 0 | -11 | — | — | — | — | — | — | |
| Operating Income | -21 | -22 | 9 | — | — | — | — | — | — | |
| Interest Expense | 59 | 58 | 72 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 72 | 70 | -1,071 | — | — | — | — | — | — | |
| Net Income Before Taxes | -8 | -9 | -1,133 | — | — | — | — | — | — | |
| Income Taxes | -1 | -1 | -41 | — | — | — | — | — | — | |
| Consolidated Net Income | -8 | -8 | -1,092 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -8 | -8 | -1,092 | — | — | — | — | — | — | |
| Net Income | -8 | -8 | -1,092 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.03 | -0.04 | -5.03 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.03 | -0.04 | -5.03 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.03 | -0.04 | -5.03 | — | — | — | — | — | — | |
| EBITDA | 172 | 171 | -938 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.26 | 2.25 | 1.42 | — | — | — | — | — | — | |
| Gross Margin | 47.01 | 47.01 | 47.04 | — | — | — | — | — | — | |
| Operating Margin | -2.41 | -2.53 | 1.01 | — | — | — | — | — | — | |
| Net Margin | -0.92 | -0.92 | -122.01 | — | — | — | — | — | — | |
| Shares Outstanding | 218 | 218 | 217 | — | — | — | — | — | — | |
| Market Capitalization | 2,834 | 1,955 | 1,272 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Nassif Mikheal | CEO | Aug 04 '26 | Buy | 11.81 | 370 | 4,370 | 1,074 | Aug 06 |
| Rocklin Amy M | Former Chief Legal Officer | May 18 '26 | Option Exercise | 9.29 | 35,183 | 326,850 | 92,423 | May 19 |
| Moylan John Patrick | Chief Accounting Officer | May 04 '26 | Option Exercise | 9.53 | 4,558 | 43,438 | 18,905 | May 05 |
| Nassif Mikheal | CEO | Feb 17 '26 | Buy | 10.94 | 23 | 252 | 704 | Feb 17 |
| Nassif Mikheal | CEO | Feb 02 '26 | Buy | 10.00 | 24 | 240 | 681 | Feb 02 |
| Nassif Mikheal | CEO | Jan 26 '26 | Buy | 9.86 | 25 | 246 | 657 | Feb 02 |
| Nassif Mikheal | CEO | Jan 16 '26 | Buy | 9.33 | 137 | 1,279 | 632 | Jan 16 |
| Naemura David H. | Former CFO | Dec 01 '25 | Option Exercise | 5.98 | 12,912 | 77,214 | 93,936 | Dec 02 |
| Nassif Mikheal | CEO | Nov 03 '25 | Buy | 6.25 | 177 | 1,106 | 495 | Nov 07 |
| BOREL JAMES C | Director | Oct 27 '25 | Option Exercise | 6.19 | 3,802 | 23,535 | 96,347 | Oct 29 |
| CAPELLO JEFFREY D | Director | Oct 27 '25 | Option Exercise | 6.19 | 3,802 | 23,535 | 32,502 | Oct 29 |
| Green Ronald D | Director | Oct 27 '25 | Option Exercise | 6.19 | 1,777 | 11,000 | 18,654 | Oct 29 |
| Gupta Aashima | Director | Oct 27 '25 | Option Exercise | 6.19 | 1,777 | 11,000 | 27,790 | Oct 29 |
| RODRIGUEZ RAFAEL A | Director | Oct 27 '25 | Option Exercise | 6.19 | 1,777 | 11,000 | 20,821 | Oct 28 |
| Tobin James P | Director | Oct 27 '25 | Option Exercise | 6.19 | 1,777 | 11,000 | 43,347 | Oct 28 |